| Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009 | 2665 | 2009 |
| A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer R Rosell, J Gomez-Codina, C Camps, J Maestre, J Padille, A Canto, ... New England Journal of Medicine 330 (3), 153-158, 1994 | 1483 | 1994 |
| Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer RVN Lord, J Brabender, D Gandara, V Alberola, C Camps, M Domine, ... Clinical Cancer Research 8 (7), 2286-2291, 2002 | 951 | 2002 |
| Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non–small-cell lung cancer M Cobo, D Isla, B Massuti, A Montes, JM Sanchez, M Provencio, ... Journal of clinical oncology 25 (19), 2747-2754, 2007 | 646 | 2007 |
| The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer RM Bremnes, T Dønnem, S Al-Saad, K Al-Shibli, S Andersen, R Sirera, ... Journal of thoracic oncology 6 (1), 209-217, 2011 | 551 | 2011 |
| Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients R Rosell, KD Danenberg, V Alberola, G Bepler, JJ Sanchez, C Camps, ... Clinical Cancer Research 10 (4), 1318-1325, 2004 | 537 | 2004 |
| Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial R Rosell, J Gómez-Codina, C Camps, JJ Sánchez, J Maestre, J Padilla, ... Lung cancer 26 (1), 7-14, 1999 | 515 | 1999 |
| Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood RM Bremnes, C Camps, R Sirera Lung cancer 51 (2), 143-158, 2006 | 437 | 2006 |
| Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer D Isla, C Sarries, R Rosell, G Alonso, M Domine, M Taron, ... Annals of oncology 15 (8), 1194-1203, 2004 | 378 | 2004 |
| Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non–small-cell lung cancer E Felip, R Rosell, JA Maestre, JM Rodríguez-Paniagua, T Morán, ... Journal of clinical oncology 28 (19), 3138-3145, 2010 | 357 | 2010 |
| The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis HE Gee, FM Buffa, C Camps, A Ramachandran, R Leek, M Taylor, M Patil, ... British journal of cancer 104 (7), 1168-1177, 2011 | 309 | 2011 |
| The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer RM Bremnes, K Al-Shibli, T Donnem, R Sirera, S Al-Saad, S Andersen, ... Journal of Thoracic Oncology 6 (4), 824-833, 2011 | 306 | 2011 |
| Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients H Cortes-Funes, C Gomez, R Rosell, P Valero, C Garcia-Giron, A Velasco, ... Annals of oncology 16 (7), 1081-1086, 2005 | 285 | 2005 |
| Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III … V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ... Journal of clinical oncology 21 (17), 3207-3213, 2003 | 260 | 2003 |
| Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF … M Martin, A Villar, A Sole-Calvo, R Gonzalez, B Massuti, J Lizon, ... Annals of Oncology 14 (6), 833-842, 2003 | 232 | 2003 |
| Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients R De las Peñas, M Sanchez-Ronco, V Alberola, M Taron, C Camps, ... Annals of Oncology 17 (4), 668-675, 2006 | 222 | 2006 |
| Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? RM Bremnes, R Sirera, C Camps Lung cancer 49 (1), 1-12, 2005 | 192 | 2005 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 176 | 2017 |
| Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial C Camps, B Massuti, A Jimenez, I Maestu, RG Gómez, D Isla, ... Annals of Oncology 17 (3), 467-472, 2006 | 170 | 2006 |
| Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non–small-cell lung cancer M Di Maio, F Perrone, P Chiodini, C Gallo, C Camps, W Schuette, E Quoix, ... Journal of Clinical Oncology 25 (11), 1377-1382, 2007 | 167 | 2007 |
